Literature DB >> 2512133

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.

M L Grayson1, G M Eliopoulos, M J Ferraro, R C Moellering.   

Abstract

The susceptibility of 22 clinical isolates of Campylobacter pylori to eight antimicrobial agents was studied under varying pH conditions. Macrolides (erythromycin, dirythromycin), clindamycin and to a lesser extent quinolones lost efficacy at lowered pH. The activity of ampicillin and metronidazole remained relatively stable throughout the pH range tested. The effect of pH an antimicrobial efficacy may warrant consideration when selecting an antibiotic to clear Campylobacter pylori in vivo, since the pH of the gastric submucous environment is not known for certain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512133     DOI: 10.1007/bf01963775

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.

Authors:  B J Marshall; C S Goodwin; J R Warren; R Murray; E D Blincow; S J Blackbourn; M Phillips; T E Waters; C R Sanderson
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

2.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

3.  Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach.

Authors:  J W Stone; R Wise; I A Donovan; J Gearty
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

4.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Campylobacter-like organisms in the stomach of patients and healthy individuals.

Authors: 
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

6.  Treatment failure of ofloxacin in Campylobacter pylori infection.

Authors:  Y Glupczynski; M Labbe; A Burette; M Delmee; V Avesani; C Bruck
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

7.  Demonstration of a pH gradient across mucus adherent to rabbit gastric mucosa: evidence for a 'mucus-bicarbonate' barrier.

Authors:  S E Williams; L A Turnberg
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

8.  Amoxycillin plus tinidazole for Campylobacter pylori gastritis in children: assessment by serum IgG antibody, pepsinogen I, and gastrin levels.

Authors:  G Oderda; D Vaira; J Holton; C Ainley; F Altare; N Ansaldi
Journal:  Lancet       Date:  1989-04-01       Impact factor: 79.321

9.  Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.

Authors:  D L Shungu; D R Nalin; R H Gilman; H H Gadebusch; A T Cerami; C Gill; B Weissberger
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

10.  Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH.

Authors:  A Morris; G Nicholson
Journal:  Am J Gastroenterol       Date:  1987-03       Impact factor: 10.864

View more
  45 in total

1.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

2.  In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.

Authors:  Osamu Kamoda; Kinsei Anzai; Jun-ichi Mizoguchi; Masatoshi Shiojiri; Toshiharu Yanagi; Takeshi Nishino; Shigeru Kamiya
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Functional relationship between bacterial cell density and the efficacy of antibiotics.

Authors:  Klas I Udekwu; Nicholas Parrish; Peter Ankomah; Fernando Baquero; Bruce R Levin
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

4.  Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.

Authors:  Y J Debets-Ossenkopp; F Namavar; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

Review 5.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

6.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.

Authors:  Mateusz Kurzawski; Barbara Gawrońska-Szklarz; Joanna Wrześniewska; Andrzej Siuda; Teresa Starzyńska; Marek Droździk
Journal:  Eur J Clin Pharmacol       Date:  2006-08-16       Impact factor: 2.953

7.  Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.

Authors:  Ahmad Settin; Ahmad Fathy Abdalla; Ayman S Al-Hussaini; Rizk El-Baz; Amr Galal
Journal:  Indian J Gastroenterol       Date:  2014-03-08

Review 8.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

9.  Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Authors:  Seung Bae Yoon; Jae Myung Park; Jong-Yul Lee; Myong Ki Baeg; Chul-Hyun Lim; Jin Soo Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Myung-Gyu Choi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Kunio Iwatsuka; Mitsuhiko Moriyama
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.